|
US20020081298A1
(en)
*
|
1997-01-07 |
2002-06-27 |
Habib Zaghouani |
Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
|
|
EP1489100B1
(en)
|
1997-12-08 |
2016-06-15 |
Merck Patent GmbH |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
|
AU5090899A
(en)
*
|
1998-07-06 |
2000-01-24 |
University Of Tennessee Research Corporation, The |
Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
|
|
EP1104456A1
(en)
*
|
1998-08-10 |
2001-06-06 |
Chiron Corporation |
Engineered antigen-presenting cells expressing an array of antigens and uses thereof
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
JP4793971B2
(ja)
|
1999-08-09 |
2011-10-12 |
メルク パテント ゲーエムベーハー |
複合サイトカイン−抗体複合体
|
|
EP1598370A3
(en)
*
|
1999-10-27 |
2006-05-10 |
Cel-Sci Corporation |
Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions
|
|
JP2003514828A
(ja)
*
|
1999-10-27 |
2003-04-22 |
セル−サイ・コーポレーシヨン |
自己免疫および移植組織に関連する宿主対移植片症状の処置に有用なペプチド構築物の調製法および組成物
|
|
EP1228214A2
(en)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietin forms with improved properties
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
EP1292621B1
(en)
*
|
2000-06-05 |
2006-09-20 |
University of Tennessee Corporation |
Compositions for treating autoimmune disease
|
|
DE60129695T2
(de)
|
2000-06-29 |
2008-06-05 |
Merck Patent Gmbh |
Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
|
|
AU2002248571B2
(en)
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
PT1383785E
(pt)
|
2001-05-03 |
2011-06-28 |
Merck Patent Gmbh |
Anticorpo recombinante específico de tumores e utilização deste
|
|
PT1454138E
(pt)
|
2001-12-04 |
2012-03-28 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
AU2003230830A1
(en)
|
2002-04-09 |
2003-10-27 |
The Curators Of The University Of Missouri |
Treatment of type 1 diabetes before and after expression of predisposition markers
|
|
US8603472B2
(en)
*
|
2002-04-09 |
2013-12-10 |
The Curators Of The University Of Missouri |
Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
|
|
US8609091B2
(en)
|
2002-04-09 |
2013-12-17 |
The Curators Of The University Of Missouri |
Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
|
|
US8603471B2
(en)
*
|
2002-04-09 |
2013-12-10 |
The Curators Of The University Of Missouri |
Methods and compositions for preventing the onset of type 1 diabetes
|
|
US7744876B2
(en)
|
2002-04-09 |
2010-06-29 |
The Curators Of The University Of Missouri |
Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
|
|
CA2526950C
(en)
*
|
2002-05-27 |
2012-06-26 |
Leif Hakansson |
Method for determining immune system affecting compounds
|
|
CN100432105C
(zh)
|
2002-12-17 |
2008-11-12 |
默克专利有限公司 |
与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
|
|
CA2551915C
(en)
|
2003-12-30 |
2015-06-23 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Il-7 fusion proteins
|
|
JP2008504008A
(ja)
|
2003-12-31 |
2008-02-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
|
|
AU2005203962C1
(en)
|
2004-01-05 |
2012-11-08 |
Antisoma Research Limited |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
SE0402536D0
(sv)
|
2004-10-20 |
2004-10-20 |
Therim Diagnostica Ab |
Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
|
|
CN101072793B
(zh)
|
2004-12-09 |
2012-06-20 |
默克专利有限公司 |
具有降低的免疫原性的il-7变体
|
|
EP1875246B1
(en)
*
|
2005-04-15 |
2016-10-05 |
CanImGuide Therapeutics AB |
Diagnostic method for detecting cancer by measuring amount of a cytokine like il-6
|
|
DK3130602T3
(da)
|
2007-05-08 |
2019-11-04 |
Canimguide Therapeutics Ab |
Immunregulerende strukturer fra normalt forekommende proteiner
|
|
EP2421896A1
(en)
|
2009-04-22 |
2012-02-29 |
Merck Patent GmbH |
Antibody fusion proteins with modified fcrn binding sites
|
|
WO2012021512A2
(en)
|
2010-08-10 |
2012-02-16 |
Ecole Polytechnique Federale De Lausanne |
Erythrocyte-binding therapeutics
|
|
US9517257B2
(en)
|
2010-08-10 |
2016-12-13 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
US9850296B2
(en)
|
2010-08-10 |
2017-12-26 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Erythrocyte-binding therapeutics
|
|
US10046056B2
(en)
|
2014-02-21 |
2018-08-14 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
KR102717969B1
(ko)
|
2014-02-21 |
2024-10-15 |
에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) |
글리코타겟팅 치료제
|
|
US10953101B2
(en)
|
2014-02-21 |
2021-03-23 |
École Polytechnique Fédérale De Lausanne (Epfl) |
Glycotargeting therapeutics
|
|
US10946079B2
(en)
|
2014-02-21 |
2021-03-16 |
Ecole Polytechnique Federale De Lausanne |
Glycotargeting therapeutics
|
|
US10441649B2
(en)
|
2015-02-02 |
2019-10-15 |
The University Of Birmingham |
Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
|
|
US11253579B2
(en)
|
2017-06-16 |
2022-02-22 |
The University Of Chicago |
Compositions and methods for inducing immune tolerance
|
|
EA202092723A1
(ru)
|
2018-05-09 |
2021-04-09 |
Зе Юниверсити Оф Чикаго |
Композиции и способы, касающиеся иммунной толерантности
|